http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022363732-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf8a3231cd88b81a086ffdc933fdef2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b938e146229db0980a37904b361ea3d4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10043 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d22f8f554c149691a524f54b2654aa5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6c2623c26c5c0244379bdec76bda2b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_240b1936f012f9745596237e21a43e32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01ccfbd3462dfc52954b3321a22ebe83 |
| publicationDate | 2022-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022363732-A1 |
| titleOfInvention | Cd5 specific t cell receptor cell or gene therapy |
| abstract | The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides nucleic acids encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a peptide from the T-cell lineage specific antigen CD5, preferably SEQ ID NO: 1 or 33, in the context of a human MHC I such as HLA-A*02, in particular HLA-A*02:01. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, expressing said TCR construct. Treatment optionally is in the context of allogeneic stem cell transplantation, in particular, mismatch-transplantation, or haploidentical transplantation, or in combination with an agent capable of inhibiting expression of HLA-A*02 in the TCR-transgenic T cells. The invention thus also provides compositions and kits comprising the nucleic acids of the invention in combination with an agent capable of inhibiting expression of HLA-A*02, and, as well as the medical use of such compositions and kits. The nucleic acids, compositions and kits, proteins or host cells may be for use in the diagnosis, prevention and/or treatment of a CD5-positive T-cell lymphoma or T-cell leukemia, no matter whether the antigen is expressed on the cell surface, intracytoplasmic or in both manners. |
| priorityDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.